The Viral Malignancy Program consists of 12 Participating and Distinguished Members, representing total peer-reviewed funding of nearly $5.5 Million in annual direct costs ($6.9 Million in total costs). During the last two years, its Members were responsible for a total of 55 cancer relevant, peer-reviewed publications 56% of which were intra-and inter-programmatic collaborations. Research on viral malignancies presents a unique opportunity for our understanding of oncogenesis and means for targeted intervention. The Viral Malignancy Program at the UCSD Cancer Center consists of a longstanding cohesive group of researchers, with wide-ranging expertise in oncogenic viruses. The current primary interests of the Program Members are focused on human retroviruses (including both HIV and HTLV), EBV, HHV-8 and HBV/HCV. Program Members investigate the pathogenesis of malignancies induced by these viruses as well as develop and test reagents such as ribozyme gene therapy, to combat these oncogenic viruses and/or their associated malignancies. Work on host- virus interactions has spawned numerous interactions and collaborations to developed and implement high-density array technology for analysis of cellular gene expression. In the induction and progression of viral malignancy. Members also study interactions between hepatitis and AIDS viruses in inducing neoplasia. Clinical trials are in progress to test a number of new anti-viral strategies in AIDS-related or hepatitis-related malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA023100-18
Application #
6466597
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1978-04-01
Project End
2006-04-30
Budget Start
Budget End
Support Year
18
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Dow, Michelle; Pyke, Rachel M; Tsui, Brian Y et al. (2018) Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 115:E9879-E9888
Que, Xuchu; Hung, Ming-Yow; Yeang, Calvin et al. (2018) Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558:301-306
Murzin, Vyacheslav L; Woods, Kaley; Moiseenko, Vitali et al. (2018) 4? plan optimization for cortical-sparing brain radiotherapy. Radiother Oncol 127:128-135
Norton, Jeffrey A; Kim, Teresa; Kim, Joseph et al. (2018) SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg 22:32-42
Ikeda, Sadakatsu; Tsigelny, Igor F; Skjevik, Åge A et al. (2018) Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 23:586-593
Buckley, Alexandra R; Ideker, Trey; Carter, Hannah et al. (2018) Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas. Genome Med 10:69
Parish, Austin J; Nguyen, Vi; Goodman, Aaron M et al. (2018) GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 124:4080-4089
Xu, Selene; Thompson, Wesley; Ancoli-Israel, Sonia et al. (2018) Cognition, quality-of-life, and symptom clusters in breast cancer: Using Bayesian networks to elucidate complex relationships. Psychooncology 27:802-809
Tao, Li; Schwab, Richard B; San Miguel, Yazmin et al. (2018) Breast Cancer Mortality in Older and Younger Breast Cancer Patients in California. Cancer Epidemiol Biomarkers Prev :
Sagredo, Eduardo A; Blanco, Alejandro; Sagredo, Alfredo I et al. (2018) ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biol Res 51:36

Showing the most recent 10 out of 862 publications